Phenotypic and genotypic characteristics of persistent methicillin- resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model

Journal of Infectious Diseases

Volumn 199, Issue 2, 2009, Pages 201-208

  Xiong, Yan Q ^a,b,g   Fowler Jr , Vance G ^d   Yeaman, Michael R ^a,b   Perdreau Remington, Francoise ^c   Kreiswirth, Barry N ^e,f   Bayer, Arnold S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFENSIN; FIBRINOGEN; FIBRONECTIN; VANCOMYCIN;

ADHESION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL VIRULENCE; CAP8 GENE; CNA GENE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; GENOTYPE; HUMAN; IN VITRO STUDY; MEMBRANE FLUIDITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TST 1 GENE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; GENOTYPE; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; RABBITS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 58849098135     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/595738     Document Type: Article

References (34)

1. Fowler VG Jr, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190:1140-9.
2. El-Ahdab F, Benjamin DK Jr, Wang A, et al. Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am J Med 2005; 118:225-9.
3. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38:7-14.
4. Fowler VG Jr, McIntyre LM, Yeaman MR, et al. In vitro resistance to thrombin-induced platelet microbicidal protein in isolates of Staphylococcus aureus from endocarditis patients correlates with an intravascular device source. J Infect Dis 2000; 182:1251-4.
5. Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157-61.
6. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3:710-20.
7. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3114-21.
8. White SH, Wimley WC, Selsted ME. Structure, function, and membrane integration of defensins. Curr Opin Struct Biol 1995; 5:521-7.
9. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6:173-82.
10. Kupferwasser LI, Yeaman MR, Nast CC, et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest 2003; 112:222-33.
11. Xiong YQ, Bayer AS, Yeaman MR, Van Wamel W, Manna AC, Cheung AL. Impacts of sarA and agr in Staphylococcus aureus strain Newman on fibronectin-binding protein A gene expression and fibronectin adherence capacity in vitro and in experimental infective endocarditis. Infect Immun 2004; 72:1832-6.
12. Fu Y, Ibrahim AS, Sheppard DC, et al. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol 2002; 44:61-72.
13. Yeaman MR, Sullam PM, Dazin PF, Norman DC, Bayer AS. Characterization of Staphylococcus aureus-platelet binding by quantitative flow cytometric analysis. J Infect Dis 1992; 166:65-73.
14. Bayer AS, Prasad R, Chandra J, et al. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect Immun 2000; 68:3548-53.
15. Dhawan VK, Bayer AS, Yeaman MR. In vitro resistance to thrombin-induced platelet microbicidal protein is associated with enhanced progression and hematogenous dissemination in experimental Staphylococcus aureus infective endocarditis. Infect Immun 1998; 66:3476-9.
16. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15.
17. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 2004; 186:1518-30.
18. Melles DC, Gorkink RF, Boelens HA, et al. Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus. J Clin Invest 2004; 114:1732-40.
19. Fowler VG Jr, Nelson CL, McIntyre LM, et al. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis 2007; 196:738-47.
20. Harmsen D, Claus H, Witte W, et al. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 2003; 41:5442-8.
21. Koreen L, Ramaswamy SV, Graviss EA, Naidich S, Musser JM, Kreiswirth BN. spa typing method for discriminating among Staphylococcus aureus isolates: implications for use of a single marker to detect genetic micro-and macrovariation. J Clin Microbiol 2004; 42:792-9.
22. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40:4289-94.
23. Entenza JM, Foster TJ, Ni Eidhin D, Vaudaux P, Francioli P, Moreillon P. Contribution of clumping factor B to pathogenesis of experimental endocarditis due to Staphylococcus aureus. Infect Immun 2000; 68:5443-6.
24. Xiong YQ, Willard J, Yeaman MR, Cheung AL, Bayer AS. Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental infective endocarditis. J Infect Dis 2006; 194:1267-75.
25. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 2006; 193:1495-503.
26. Bayer AS, Coulter SN, Stover CK, Schwan WR. Impact of the high-affinity proline permease gene (putP) on the virulence of Staphylococcus aureus in experimental endocarditis. Infect Immun 1999; 67:740-4.
27. Dhawan VK, Yeaman MR, Bayer AS. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis. J Infect Dis 1999; 180:1561-8.
28. Dhawan VK, Yeaman MR, Cheung AL, Kim E, Sullam PM, Bayer AS. Phenotypic resistance to thrombin-induced platelet microbicidal protein in vitro is correlated with enhanced virulence in experimental endocarditis due to Staphylococcus aureus. Infect Immun 1997; 65:3293-9.
29. Que YA, Haefliger JA, Piroth L, et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med 2005; 201:1627-35.
30. Elasri MO, Thomas JR, Skinner RA, et al. Staphylococcus aureus collagen adhesin contributes to the pathogenesis of osteomyelitis. Bone 2002; 30:275-80.
31. Galperine T, Neau D, Lina G, et al. Menstrual staphylococcal toxic shock is still a reality [in French]. Presse Med 2003; 32:1121-2.
32. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007; 167:1861-7.
33. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51.
34. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8.